INTERCOMMUNITY CANCER CENTERS NOW USING CALYPSO®, “GPS FOR THE BODY”™ FOR TREATMENT OF PROSTATE CANCER
ICCC is the First in Lake, Sumter and Marion Counties to Offer New Precision-Guided Technology
LADY LAKE, Fla. - March 07, 2008 — InterCommunity Cancer Centers announced today that it is the first cancer-care program in Lake, Sumter and Marion Counties to provide prostate cancer patients access to the Calypso® 4D Localization System™ for use in prostate cancer radiation treatment.
This new form of technology, called GPS for the Body®, allows precision-guided radiation therapy delivery to the prostate with continuous, prostate-motion detection and monitoring. Essentially, Calypso tells the physician where the tumor location is at all times during daily radiation treatments. Movement of prostate tumors can occur during and in between treatments as a result of body physiology. This daily organ motion can result in ineffective delivery of radiation and damage surrounding healthy tissues. Calypso was designed to “track” the location of the prostate tumor during oncology treatments to precisely and continuously target the delivery of the external beam to the position of the tumor. |
“New technologies such as the Calypso System deliver higher doses of radiation with fewer complications and side effects than patients typically experience when treated with conventional radiation therapy,” said Hal M. Jacobson, M.D., founder and President of InterCommunity Cancer Centers and Cancer Care Associates, P.A. “With the multi-disciplinary approach to treating malignancies today, our new technology will undoubtedly result in optimal results for the patient.
ABOUT INTERCOMMUNITY CANCER CENTERS (Leesburg and Lady Lake, FL)
The Technology Leadership of the InterCommunity Cancer Center discovers and provides new techniques and skills ahead of most universities and other cancer centers. Founded in 1985 by Dr. Hal M. Jacobson, this leadership has been recognized at State and National levels by requests to provide invited lectures to University and National Conferences as well as development and educational consulting services to major corporations. All ICCC physicians are Board Certified and practice in affiliation with Moffitt Cancer Institute. Locations in Lady Lake and Leesburg were created to provide this expertise in the comfort of the patient’s own community avoiding the risks, stress, and cost of extensive travel. ICCC also provides coordination of health care services with a variety of conventional and complementary practitioners for all forms of cancer. Among the treatment options they offer: first in the area to offer IMRT, MammoSite breast treatment, prostate “seed” implants, Varian Clinac Linear Accelerators, H.D.R.Brachytherapy, XiO 3-D Treatment Planning System and FOCAL virtual simulation, KODAK AccuLoc based and ultrasound based IGRT, first in the State of Florida to offer Cesium-131 seeds, dedicated CT Scan Treatment Simulator and Virtual Simulation of treatments for precision planning. The advanced technology is managed by an experienced team of experts including Dosimetrists, Radiation Therapists, and Medical Physicists.
ABOUT VANTAGE ONCOLOGY, INC.
Founded in October 2002, El Segundo, California-based Vantage Oncology, Inc. acquires, joint ventures, develops and operates state-of-the-art radiation oncology centers. Vantage Oncology was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage Oncology is led by a seasoned management team, including Chief Executive Officer Michael Fiore, Medical Director Leslie Botnick, M.D., Chief Financial Officer Marshal Salomon and Chief Development Officer Mark Ahern. For more information about Vantage Oncology, visit www.vantageoncology.com.
ABOUT CALYPSO® MEDICAL TECHNOLOGIES, INC.
Calypso® Medical Technologies, Inc. (“Calypso”) is a Seattle, WA based privately held medical device company. The Company’s proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately, and objectively pinpoint the location of tumors for improved accuracy in radiation therapy. Calypso Medical addresses two major issues in modern radiation oncology: errors in treatment set-up and tumor motion during treatment. In addition, the Calypso® 4D Localization System™’s non-ionizing electromagnetic guidance has the potential to improve work flow efficiency and treatment room utilization. The technology is designed for body-wide cancers commonly treated with radiation therapy, including prostate, breast, lung, head, neck and other radiation therapy target organs. The transponder is FDA 510(k) cleared for use in the prostate.Calypso®, Beacon®, and GPS for the Body® are registered trademarks, and Motion Matters™, On Target, On With Living™, Beacon Within™, 4D Localization System™, 4D Console™, 4D Electromagnetic Array™ and 4D Tracking Station™ are trademarks of Calypso® Medical Technologies, Inc.
CONTACT:
Trace Longo
Longo Communications
(949) 364-2821
Deborah Reagan
Marketing Coordinator
(352) 326-2224 |
